CORDIS
EU research results

CORDIS

English EN
A Low Cost, Environmentally, Friendly Smart Packaging Technology to Differentiate European SME Suppliers to Service the Needs of the Blind, Illiterate and Europe's Aging Population.

A Low Cost, Environmentally, Friendly Smart Packaging Technology to Differentiate European SME Suppliers to Service the Needs of the Blind, Illiterate and Europe's Aging Population.

Objective

Printed instructions are meaningless to around 20% of the European Population. This figure, combined with the 8million registered blind and partially sighted as well as the ever increasing aging population are contributing to the 194,500 deaths a year in the EU due to miss-dose and non-compliance of prescribed medication. Non-compliance is estimated to cost the European Union 125bn euros annually, of which 2.25bn euros is annually paid by Europe's struggling SME pharmacist community. Our idea is to take current state-of-the-art compliance monitoring, enhance it and combine it with our speech technology incorporating them into Pharmaceutical blister packaging through novel manufacturing techniques such as In-mould labelling, over moulding and encapsulation. These technologies will overcome the problems associated with non-compliance and miss-dose, specifically through the incorporation of Spoken instructions. Further more, the primary objective of the project is to develop an eco-friendly power generation system that will harness 'free' solar energy through the incorporation of thin film, flexible, photovoltaic laminates, with specific innovation being in the homogenisation of the photovoltaic and the polymer packaging through in-mould labelling techniques. The speech system and compliance electronics will be developed onto a flexible PCB which will be over-moulded enabling incorporation into the packaging ensuring that the instructions are never lost from the medication. The spoken instructions will be heard through a piezo-electric sounder that will be encapsulated into the polymer packaging during the injection moulding process. Dosage assurance will be achieved through the printing of conductive ink electrodes onto the blister sealing film that will input to the compliance circuitry. The technical risks are high, but justified by the huge economic, social and environmental benefits, and are addressed through a methodical and structured program of work.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MEGAVOICE IRELAND LTD

Address

Slieve Gallion, 8a Drumullan Road, Moneymore
Co Londonderry, Northern Ireland

United Kingdom

Administrative Contact

W. B. TURKINGTON (Mr)

Participants (10)

Sort alphabetically

Expand all

A K INDUSTRIES LIMITED

United Kingdom

CENTRE DE RECERCA I INVESTIGACIO DE CATALUNYA S A

Spain

FAROMED H.GES.M.B.H

Austria

IT MOBILE OY

Finland

MTC HOLDING GMBH

Austria

MTC POLSKA SP.Z.O.O

Poland

NOVARTIS PHARMA AG

Switzerland

PERA INNOVATION LIMITED

United Kingdom

ROYAL NATIONAL INSTITUTE OF THE BLIND

United Kingdom

UNIA FARMACEUTOW - WLASCICIELI APTEK

Poland

Project information

Grant agreement ID: 17893

  • Start date

    1 September 2005

  • End date

    29 February 2008

Funded under:

FP6-SME

  • Overall budget:

    € 1 325 479

  • EU contribution

    € 686 562

Coordinated by:

MEGAVOICE IRELAND LTD

United Kingdom